Last $3.85 USD
Change Today -0.08 / -2.04%
Volume 186.9K
BCLI On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ CM
As of 8:10 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

brainstorm cell therapeutics (BCLI) Snapshot

Open
$3.90
Previous Close
$3.93
Day High
$3.93
Day Low
$3.75
52 Week High
01/2/15 - $8.47
52 Week Low
12/12/14 - $2.81
Market Cap
69.3M
Average Volume 10 Days
347.7K
EPS TTM
--
Shares Outstanding
18.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BRAINSTORM CELL THERAPEUTICS (BCLI)

brainstorm cell therapeutics (BCLI) Related Bloomberg News

View More Bloomberg News

brainstorm cell therapeutics (BCLI) Related Businessweek News

No Related Businessweek News Found

brainstorm cell therapeutics (BCLI) Details

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor and brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. It is developing NurOwn, an autologous adult stem cell product for the treatment of ALS. Brainstorm Cell Therapeutics Inc. also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics was founded in 2000 and is based in New York, New York.

15 Employees
Last Reported Date: 11/13/14
Founded in 2000

brainstorm cell therapeutics (BCLI) Top Compensated Officers

President
Total Annual Compensation: --
Chief Financial Officer and Principal Account...
Total Annual Compensation: $106.0K
Compensation as of Fiscal Year 2013.

brainstorm cell therapeutics (BCLI) Key Developments

BrainStorm Cell Therapeutics Inc. Announces Positive Results from Preclinical Studies of NurOwn™ in the BTBR Mouse Model of Autism

BrainStorm Cell Therapeutics Inc. announced positive results from preclinical studies of NurOwn™ in the BTBR mouse model of autism. NurOwn™ cells are mesenchymal stem cells (MSCs) that have been induced, under BrainStorm's proprietary methods, to secrete a variety of neurotrophic factors. The BTBR mouse exhibits several stereotypical behavioral characteristics that resemble behaviors seen in autism spectrum disorders, including repetitive behaviors, altered social interactions, cognitive rigidity and impaired adaption to environment. These studies, conducted in collaboration with Professor Dani Offen, PhD, of Tel Aviv University Chief Scientific Advisor to BrainStorm, assessed the ability of NurOwn™ cells to affect the behavior of BTBR mice. Across all the measures, including assessments of repeated self-grooming, social interaction and cognitive rigidity, NurOwn™ cells demonstrated marked behavioral benefits in BTBR mice after a single treatment, as compared to control group, which consisted of BTBR mice treated only with vehicle. NurOwn™ cells performed particularly well in an important assessment of reversal of learning. This test evaluates the time it takes to the mice to maneuver in a water maze after the maze was first learned and then altered. In this cognitive rigidity test, NurOwn™-treated BTBR mice adapted quickly to the new conditions, taking 60% less time than the control BTBR mice to relearn the maze (p=0.016). Notably, the cognitive rigidity and social grooming behavior of the treated BTBR mice were similar to those behaviors observed in a normal mouse strain (C57/BL).

Brainstorm Cell Therapeutics Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-19-2015 04:30 PM

Brainstorm Cell Therapeutics Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-19-2015 04:30 PM. Venue: Club Med, Sandpiper Bay, Florida, United States. Speakers: Anthony Fiorino, Chief Executive Officer.

Brainstorm Cell Therapeutics Inc. Announces Final Analysis of Phase 2A ALS Study Showing Nearly All Subjects Experienced Clinical Benefit from Nurown™

Brainstorm Cell Therapeutics Inc. announced positive final results from its phase 2a clinical trial of NurOwn in amyotrophic lateral sclerosis (ALS) patients, which enrolled 14 subjects at Hadassah Medical Center in Jerusalem. The study achieved its primary endpoint in demonstrating that NurOwn is safe and well-tolerated at doses up to 2 million cells per kilogram administered intrathecally (IT) and 48 million cells administered intramuscularly (IM). Importantly, nearly all subjects in this study experienced clinical benefit from treatment with NurOwn. Of the 12 subjects with three or more months of follow-up, 92% experienced an improvement in the rate disease progression for the three month period after administration of NurOwn, as measured by ALS Functional Rating Score-Revised (ALSFRS) or forced vital capacity (FVC). 50% had an improvement in the slope of the ALSFRS score, and 67% had an improvement in the slope of the percent-predicted FVC. NurOwn slowed the progression of ALS in this study, as indicated by an improving slope of both the mean ALSFRS and mean FVC curves after therapy. On ALSFRS, NurOwn slowed the rate of progression by 45%, from 1.41 points per month during the run-in period to 0.78 points per month for the three months following treatment, and by 57% to 0.60 per month for the six months following treatment. NurOwn had a similarly strong effect on the progressive loss of lung function the rate of decline in percent-predicted FVC was reduced by 73%, from an average of 2.60% per month during the run-in period to just 0.70% per month for the three months after treatment, and by 67% to 0.86% per month for the six months following treatment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCLI:US $3.85 USD -0.08

BCLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BCLI.
View Industry Companies
 

Industry Analysis

BCLI

Industry Average

Valuation BCLI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRAINSTORM CELL THERAPEUTICS, please visit www.brainstorm-cell.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.